In the recent decade, second-generation hormonal therapies such as abiraterone [5], apalutamide [6], enzalutamide [7], and darolutamide [8] have been developed to re-target the AR and have significantly improved the survival of PC patients. This evidence concerns the gene AR and pachyonychia congenita.